<DOC>
	<DOCNO>NCT01232647</DOCNO>
	<brief_summary>Vitamin K think important bone health activate several protein involve bone formation . Poor dietary intake vitamin K ( mainly find dark green leafy vegetable ) associate bone loss fracture . Giving supplement main dietary form vitamin K ( call K1 ) another common form body make K1 ( call MK4 ) , improve bone health give mixed result . This confusion think arisen study involve people already enough vitamin K osteoporosis . We want test hypothesis treatment bisphosphonates combine vitamin K , vitamin K deplete elderly woman osteoporosis , may offer additional benefit skeletal metabolism reduction fracture risk . We want test measuring vitamin K status post-menopausal woman osteoporosis recommend treatment bisphosphonate calcium/vitamin D supplement . Those low vitamin K recruit study effect supplementation either K1 MK4 .</brief_summary>
	<brief_title>Vitamin K Additive Treatment Osteoporosis</brief_title>
	<detailed_description>Vitamin K important skeletal health . Vitamin K essential carboxylation several Gla proteins bone implicate bone formation mineralization . These include osteocalcin ( OC ) matrix Gla protein ( MGP ) . Carboxylation glutamic acid residue proteins optimises function . Vitamin K occur either phylloquinone ( vitamin K1 ) major dietary form menaquinones ( MKs vitamin K2 ) mainly bacterial origin . MK4 vitamin K2 series additional , carboxylation-independent , function include regulation osteoblastic specific marker alkaline phosphatase ( BALP ) , osteoprotegerin ( OPG ) inhibitory effect osteoclast activity . Several observational study show low vitamin K status associate low bone mineral density ( BMD ) increase fracture risk , although proof causality lacking . The result several placebo-controlled clinical trial vitamin K1 MK4 conflicting , , show positive effect vitamin K1 BMD bone turnover . Positive fracture efficacy demonstrate high-dose MK4 , although trial Japanese woman . These intervention study may hamper study design inclusion vitamin K replete subject healthy non-osteoporotic woman . The use vitamin K prevention bone loss and/or fracture high-risk post-menopausal woman osteoporosis vitamin K deplete merit investigation . The prevalence low vitamin K store high elderly subject osteoporosis . Preliminary data Japanese woman suggest combine treatment bisphosphonate vitamin K , least vitamin K2 ( MK4 ) , appear additive beneficial effect BMD bone resorption . There study caucasian osteoporotic population . We want test hypothesis treatment bisphosphonates combine vitamin K , vitamin K deplete elderly woman osteoporosis , may offer additional benefit skeletal metabolism reduction fracture risk . The first part cross-sectional study post-menopausal woman osteoporosis age 60-80 year treatment bisphosphonate . Their vitamin K status determine patient find low vitamin K concentration define &lt; 0.15 ug/ml invite take part 18 month prospective randomise placebo control trial . Eligible patient randomise 3 arm ( 50 patient arm ) . All 3 group continue receive weekly oral bisphosphonate ( commonly Alendronate 70 mg weekly ) adjunctive calcium/vitamin D supplement ( 1.0g calcium 800 I.U cholecalciferol ) . The control arm ( Group A ) receive placebo . Group B receive 1.0mg daily vitamin K1 MK4 placebo . Group C receive vitamin K2 ( MK4 ) 45 mg daily vitamin K1 placebo . Patients see baseline 3 , 6 , 12 18 month . Changes BMD lumbar spine , hip , fore-arm 18 month biochemical parameter time point compare group .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<criteria>Inclusion crosssectional part study involve assessment vitamin K status 1 . Informed consent screen stage : assessment vitamin K status 2. serum vitamin K concentration &lt; 0.15 ug/ml Inclusion randomise control trial 1. ambulatory postmenopausal woman age 5585 year 2 . Postmenopausal osteoporosis ( history previous fragility fracture BMD evidence osteoporosis osteopenia least one clinical risk factor low BMI , positive family history osteoporosis ) 3 . Treatment bisphosphonate calcium/vitamin D supplement least 12 month 4 . Informed write consent 5. e GFR &gt; 30 ml/min 6. normocalcaemia 1 . Age &lt; 55 year , &gt; 85 year 2 . Male gender 3. severe renal impairment ( CKD stage 4 5 ) 4. poor mobility ( inability walk 100 yard unaided ) 5. malabsorption ( extensive bowel surgery , short bowel ) 6. generalised carcinomatosis 7. glucocorticoid therapy 8. inflammatory disorder ( e.g . active rheumatoid arthritis , inflammatory bowel disease require oral glucocorticoid ) , 9. endocrine disease ( e.g . primary hyperparathyroidism , hyperthyroidism ) . 10. chronic liver disease 11. current treatment teriparatide , strontium ranelate 12 . Participation trial investigational product within previous 3 month 13 . Serum vitamin K &gt; 0.15 Âµg/ml 14. patient anticoagulant warfarin</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>vitamin K</keyword>
	<keyword>BONE MINERAL DENSITY</keyword>
	<keyword>BIOCHEMICAL MARKERS OF BONE TURNOVER</keyword>
</DOC>